Perry B. Molinoff

Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA.

Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada.

Cynapsus Therapeutics, Inc. operated as a pharmaceutical company, which developed an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. The company was founded by Andrew Williams and David Hill on January 16, 2004 and was headquartered in Toronto, Canada.

Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.

Cersci Therapeutics, Inc. operates as pharmaceutical company. The firm develops non-opioid analgesic drug products without the deleterious side effects. The company was founded by Lucas Rodriguez and Brent Duncan in 2019 and is headquartered in Dallas, TX.